Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Apr 15, 2021 4:50pm
86 Views
Post# 33005284

RE:RE:RE:RE:The problem

RE:RE:RE:RE:The problemInteresting. It was always a takeover candidate given the backing from Carlyle and Hellman Friedman private equity shops. Was public only briefly (<2 years) yet has 18 ANALYSTS COVERING IT!  Shows you how the PE/VC guys DEMAND coverage for their names and they get it.  Both firms still have 2-3 guys on the Board from their firms.  

I know THTX isn't a PE backed firm, but having some smart money guys on the Board is very valuable and they should learn that from seeing the value creation with PPD in a bried amount of time. Soleus and whomever else they brought on with the OO is the closest they will get to having those intros and favors pulled in.  They need to hit while Soleus is still hot on them. 


qwerty22 wrote: PPD in $15 billion buyout. Don't think it matter to the cancer trial, just interesting.


<< Previous
Bullboard Posts
Next >>